Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: A Southwest Oncology Group (SWOG) trialT

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 2, 2006, Pages 116-122

  Williamson, Stephen K ^a   McCoy, Sheryl A ^b   Gandara, David R ^c   Dakhil, Shaker R ^d   Yost, Kathleen J ^e   Paradelo, Jorge C ^f   Atkins, James N ^g   Blanke, Charles D ^h   Abbruzzese, James L ⁱ  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^f Kansas City Community Clinical Oncology Program   (United States)

^g Southeast Cancer Control Consortium   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Esophageal carcinoma; Gemcitabine; Irinotecan; Phase 2

Indexed keywords

GEMCITABINE; IRINOTECAN; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEATH; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DYSPNEA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KAPLAN MEIER METHOD; LETHARGY; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; WEIGHT REDUCTION; ADENOCARCINOMA; DISEASE COURSE; ESOPHAGUS TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645790827     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000199883.10685.2b     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
3. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270-3275.
4. Macdonald JS, Jacobson JL, Ketchel SJ, et al. A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339). Invest New Drugs. 2000;18:199-202.
5. Urba SG, Chansky K, VanVeldhuizen PJ, et al. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs. 2004;22:91-97.
6. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990;50:4417-4422.
7. Poplin EA, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs. 1992;10:165-170.
8. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
9. Mani S, Ratain MJ. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996;8:525-534.
10. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol. 1997;8:837-855.
11. Von Hoff DD, Burris HA 3rd, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol. 1994;34(suppl):S41-S45.
12. Shimada Y, Rothenberg M, Hilsenbeck SG, et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994;5:202-206.
13. Futatsuki K, Wakui A, Nakao I, et al. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho. 1994;21:1033-1038.
14. Sakata Y, Shimada Y, Yoshino M, et al. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. Gan To Kagaku Ryoho. 1994;21:1039-1046.
15. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11:909-913.
16. Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer. 1996;32A(suppl 3):S13-S17.
17. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol. 1998;25(suppl 11):39-46.
18. Rothenberg ML. The current status of irinotecan (CPT-11) in the United States. Ann N Y Acad Sci. 1996;803:272-281.
19. Rocha Lima CM, Leong SS, Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Huntingt). 2002;16(suppl 5):19-24.
20. Alberts SR, Erlichman C, Sloan J, et al. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Ann Oncol. 2001;12:627-631.
21. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216-1220
22. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826-1834.
23. Sandler AB, Kindler HL, Einhorn LH, et al. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000;11:1161-1164.
24. Kroep JR, Pinedo HM, Giaccone G, et al. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol. 2004;15:230-235.
25. Lin L-S HJ. A Phase II Trial of Irinotecan in Patients with Advanced Adenocarcinoma of the Gastroesophageal (GE) Junction. Proceedings of the American Society of Clinical Oncology; 2000.
26. Enzinger PKM, Clark J, Ryan D, et al. Phase II Trial of CPT-11 in Previously Untreated Patients with Advanced Adenocarcinoma of the Esophagus and Stomach. Proceedings of the American Society of Clinical Oncology; 2000.
27. Fleming TR, Brown TD, Ross SW, et al. Phase II trial of trimetrexate in advanced esophageal cancer: a Southwest Oncology Group study. Invest New Drugs. 1996;13:363-365.
28. Poplin E, Fleming T, MacDonald JS, et al. Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study. Invest New Drugs. 1993;11:47-51.
29. Govindan R, Read W, Faust J, et al. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Huntingt). 2003;17(suppl 8):27-31.
30. Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer. 2003;89:630-633.